CN113286610A - 抗her2多肽和其使用方法 - Google Patents

抗her2多肽和其使用方法 Download PDF

Info

Publication number
CN113286610A
CN113286610A CN201980068845.5A CN201980068845A CN113286610A CN 113286610 A CN113286610 A CN 113286610A CN 201980068845 A CN201980068845 A CN 201980068845A CN 113286610 A CN113286610 A CN 113286610A
Authority
CN
China
Prior art keywords
amino acid
seq
variable region
acid sequence
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980068845.5A
Other languages
English (en)
Chinese (zh)
Inventor
马克·S·丹尼斯
关艾欣
约瑟夫·W·雷洛克
乔纳森·索科洛斯基
乔伊·余·祖切罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denali Therapeutics Inc
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of CN113286610A publication Critical patent/CN113286610A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980068845.5A 2018-08-22 2019-08-22 抗her2多肽和其使用方法 Pending CN113286610A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862721505P 2018-08-22 2018-08-22
US62/721,505 2018-08-22
PCT/US2019/047728 WO2020041604A1 (en) 2018-08-22 2019-08-22 Anti-her2 polypeptides and methods of use thereof

Publications (1)

Publication Number Publication Date
CN113286610A true CN113286610A (zh) 2021-08-20

Family

ID=67989062

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980068845.5A Pending CN113286610A (zh) 2018-08-22 2019-08-22 抗her2多肽和其使用方法

Country Status (15)

Country Link
US (1) US20220002436A1 (cg-RX-API-DMAC7.html)
EP (1) EP3840781A1 (cg-RX-API-DMAC7.html)
JP (3) JP2021534220A (cg-RX-API-DMAC7.html)
KR (1) KR20210074279A (cg-RX-API-DMAC7.html)
CN (1) CN113286610A (cg-RX-API-DMAC7.html)
AR (1) AR115998A1 (cg-RX-API-DMAC7.html)
AU (2) AU2019326545A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021002953A2 (cg-RX-API-DMAC7.html)
CA (1) CA3141815A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190603A1 (cg-RX-API-DMAC7.html)
IL (2) IL326298A (cg-RX-API-DMAC7.html)
MX (1) MX2021001976A (cg-RX-API-DMAC7.html)
SG (1) SG11202101436SA (cg-RX-API-DMAC7.html)
TW (1) TW202017947A (cg-RX-API-DMAC7.html)
WO (1) WO2020041604A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025189767A1 (zh) * 2024-03-13 2025-09-18 深圳太力生物技术有限责任公司 一种重组细胞及其制备方法与应用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
JP7543290B2 (ja) 2019-02-20 2024-09-02 デナリ セラピューティクス インコーポレイテッド 抗trem2抗体及びその使用方法
BR112022012230A2 (pt) 2019-12-23 2022-08-30 Denali Therapeutics Inc Variantes de progranulina
US11124567B2 (en) 2020-01-13 2021-09-21 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
CA3170338A1 (en) * 2020-02-19 2021-08-26 Denali Therapeutics Inc. Engineered anti-her2 bispecific proteins
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
IL311003A (en) 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them
US20240392035A1 (en) * 2021-08-25 2024-11-28 Denali Therapeutics Inc. Engineered anti-her2 bispecific proteins
US20250066449A1 (en) * 2021-12-31 2025-02-27 Imnewrun, Inc. Blood-brain barrier permeable fusion protein and uses thereof
KR20240067001A (ko) * 2022-10-28 2024-05-16 주식회사 아임뉴런 뇌혈관장벽 투과성 융합 단백질 및 이의 용도
JP2025540336A (ja) * 2022-12-08 2025-12-11 アデル,インク 抗タウ抗体及びペプチドを含む融合体とその用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089209A2 (en) * 2012-12-04 2014-06-12 Abbvie, Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins
WO2015191934A2 (en) * 2014-06-11 2015-12-17 Abbvie Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
WO2016207091A1 (en) * 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE423140T1 (de) * 2005-01-05 2009-03-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
MX367126B (es) * 2012-08-29 2019-08-06 Hoffmann La Roche Transporte para atravesar la barrera hematoencefálica.
CN107446045A (zh) * 2016-07-22 2017-12-08 北京天广实生物技术股份有限公司 一种抗her2的抗体、其药物组合物及用途
RS63818B1 (sr) * 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
CA3053379A1 (en) * 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
WO2019032955A1 (en) * 2017-08-10 2019-02-14 Denali Therapeutics Inc. MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089209A2 (en) * 2012-12-04 2014-06-12 Abbvie, Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins
WO2015191934A2 (en) * 2014-06-11 2015-12-17 Abbvie Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
WO2016207091A1 (en) * 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOURA IC等: "Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy", 《J EXP MED》, vol. 194, no. 4, pages 417 - 25, XP002273386, DOI: 10.1084/jem.194.4.417 *
WEBER F 等: "Brain Shuttle Antibody for Alzheimer\'s Disease with Attenuated Peripheral Effector Function due to an Inverted Binding Mode", 《CELL REP》, vol. 22, no. 1, pages 149 - 162, XP055578810, DOI: 10.1016/j.celrep.2017.12.019 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025189767A1 (zh) * 2024-03-13 2025-09-18 深圳太力生物技术有限责任公司 一种重组细胞及其制备方法与应用

Also Published As

Publication number Publication date
IL326298A (en) 2026-04-01
JP2021534220A (ja) 2021-12-09
KR20210074279A (ko) 2021-06-21
US20220002436A1 (en) 2022-01-06
IL280922B1 (en) 2026-03-01
EA202190603A1 (ru) 2021-07-14
CA3141815A1 (en) 2020-02-27
JP2026086616A (ja) 2026-05-26
JP7818042B2 (ja) 2026-02-19
IL280922B2 (en) 2026-07-01
AU2019326545A1 (en) 2021-03-11
AR115998A1 (es) 2021-03-25
IL280922A (en) 2021-04-29
TW202017947A (zh) 2020-05-16
EP3840781A1 (en) 2021-06-30
WO2020041604A1 (en) 2020-02-27
JP2024150674A (ja) 2024-10-23
BR112021002953A2 (pt) 2021-05-11
MX2021001976A (es) 2021-06-08
AU2026200081A1 (en) 2026-01-29
SG11202101436SA (en) 2021-03-30

Similar Documents

Publication Publication Date Title
JP7818042B2 (ja) 抗her2ポリペプチド及びそれらの使用の方法
US20210130485A1 (en) Transferrin receptor-binding polypeptides and uses thereof
CN111971090A (zh) 双特异性egfr/cd16抗原结合蛋白
US20230192887A1 (en) Engineered anti-her2 bispecific proteins
US20260109781A1 (en) Anti-her2 antibodies and methods of use thereof
US20240392035A1 (en) Engineered anti-her2 bispecific proteins
US20260071002A1 (en) Antibodies binding to ceacam5
HK40084724A (en) Engineered anti-her2 bispecific proteins
HK40110414A (en) Anti-her2 antibodies and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination